This review does not provide an exhaustive, comprehensive review of the literature
With the popularity of GLP-1 agonists ever-increasing and over 150 GLP-1 drug candidates in development [3], the field is continually expanding, most recently into oncology and obesity-related cancers.[4] While most approved GLP-1RAs require subcutaneous injection, substantial work is being undertaken to move toward oral GLP-1 therapies [5], such as Rybelsus which was the first oral GLP-1RA approved by the FDA in 2019
This hormone is released after eating and plays a key role in regulating appetite, blood sugar, and digestion
That origin story is not incidental: much of the entire epithalon evidence base traces back to Khavinson's research group decades of work and a large body of published papers, the majority from the same investigators
The company said the changes were made "after careful consideration of GLP-1 weight loss drugs' efficacy, safety and access, and cost
reported improved glucose tolerance, cardiac contractility, and survival after infusion of exenatide in murine model of dilated cardiomyopathy [52]
